• Telo Genomics closed a $250,000 secured term loan with BrightArc Capital Adminco 1, effective October 29, 2026.
• The demand, non-revolving facility funds general operating expenses; an initial $100,000 has been advanced.
• Interest accrues at 1.3% monthly, equivalent to 15.6% annually; a minimum three months’ interest is payable.
• Security covers present and after-acquired personal property, including an irrevocable assignment of SR&ED tax credits and refunds.
• Repayment falls due three business days following receipt of 2026 SR&ED claims or 12 months from advance, whichever is earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telo Genomics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611061600NEWSFILECNPR____20261106_322920_1) on November 06, 2026, and is solely responsible for the information contained therein.